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Abstract
Background: The idiopathic inflammatory myopathies (IIMs) are heterogeneous autoimmune conditions of skeletal
muscle inflammation and weakness. MicroRNAs (miRNAs) are short, non-coding RNA which regulate gene
expression of target mRNAs. The aim of this study was to profile miRNA and mRNA in IIM and identify miRNA-
mRNA relationships which may be relevant to disease.
Methods: mRNA and miRNA in whole blood samples from 7 polymyositis (PM), 7 dermatomyositis (DM), 5
inclusion body myositis and 5 non-myositis controls was profiled using next generation RNA sequencing. Gene
ontology and pathway analyses were performed using GOseq and Ingenuity Pathway Analysis. Dysregulation of
miRNAs and opposite dysregulation of predicted target mRNAs in IIM subgroups was validated using RTqPCR and
investigated by transfecting human skeletal muscle cells with miRNA mimic.
Results: Analysis of differentially expressed genes showed that interferon signalling, and anti-viral response
pathways were upregulated in PM and DM compared to controls. An anti-Jo1 autoantibody positive subset of PM
and DM (n = 5) had more significant upregulation and predicted activation of interferon signalling and highlighted
T-helper (Th1 and Th2) cell pathways. In miRNA profiling miR-96-5p was significantly upregulated in PM, DM and
the anti-Jo1 positive subset. RTqPCR replicated miR-96-5p upregulation and predicted mRNA target (ADK, CD28 and
SLC4A10) downregulation. Transfection of a human skeletal muscle cell line with miR-96-5p mimic resulted in
significant downregulation of ADK.
Conclusion: MiRNA and mRNA profiling identified dysregulation of interferon signalling, anti-viral response and T-
helper cell pathways, and indicates a possible role for miR-96-5p regulation of ADK in pathogenesis of IIM.
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Background
The idiopathic inflammatory myopathies (IIMs) are a
heterogeneous group of autoimmune conditions charac-
terised by weakness and inflammation of skeletal muscle.
Major clinical classifications of IIM include polymyositis
(PM), dermatomyositis (DM) and inclusion body
myositis (IBM). Between 60 and 70% of IIM patients
have detectable myositis associated or specific autoanti-
bodies which are associated with particular clinical
phenotypes [1].
MicroRNAs (miRNAs) are short, non-coding, single-
stranded RNAs which target particular mRNAs for
translational suppression and/or degradation. In this
manner miRNAs ‘fine-tune’ gene expression and influ-
ence a wide variety of cellular processes and pathways.
MiRNAs which regulate the immune system have been
found to be dysregulated in autoimmune conditions in-
cluding IIM [2] and miRNAs important in the develop-
ment and maintenance of skeletal muscles, termed
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myomiRs, have been found to be dysregulated in IIM [3,
4]. MiRNA dysregulation has been investigated in IIM
subtypes in a variety of tissues but further research is
required to understand the role of microRNA in IIM
pathology [5].
In this study we used next generation RNA sequencing
to generate a comprehensive miRNA and mRNA profile
in whole blood of PM, DM and IBM patients and then
followed up particular miRNA-mRNA interactions by




Patients with definite IIM were recruited as part of the
Salford Royal NHS Foundation Trust myositis research
tissue bank (MRTB). All patients fulfilled Bohan and
Peter criteria for PM or DM [6, 7] and Griggs or Euro-
pean Neuromuscular Centre or Medical Research Coun-
cil criteria for IBM [8, 9]. Control samples were age and
ethnicity matched from MRTB taken for diagnostic or
treatment purposes (non-myositis controls). All clinical
data was held on the EuroMyositis database [10]. Demo-
graphic features for the 7 PM, 7 DM, 5 IBM patients and
5 non-myositis controls included in this study are sum-
marised in Table 1. Disease duration ranged from < 1
year to 10 years at time of blood sample. On average,
disease duration was slightly higher in the IBM group
(4.2 years) compared to PM, DM or anti-Jo1 positive
groups (< 3.2, < 1.7 and < 3.4 years respectively). One
antibody negative PM patient had been diagnosed with
cancer at the time of blood draw (in situ intraepithelial
non-infiltrating carcinoma).
RNA preparation and sequencing
Total RNA was extracted from whole blood using Mag-
MAX™ for stabilised blood tubes RNA Isolation Kit
(Ambion). RNA concentration and integrity was mea-
sured using Agilent RNA 6000 Nano chips on the Bioa-
nalyzer 2100. Complementary DNA (cDNA) library
preparation was performed using NEBNext® Multiplex
Small RNA Library Prep sets for Illumina using 6% Poly-
Acrylamide gel to perform size selection for miRNA
cDNA libraries. Illumina TruSeq® Stranded mRNA
library preparation kit was used for mRNA. Paired end
sequencing was performed for both libraries on an Illu-
mina HiSeq 4000. Samples were run 8 to a lane with a
read depth of approximately 39 million per sample.
RNA sequencing analysis
FastQC was used to produce quality reports for each
sample (read 1 and read 2, refer to Additional file 1 for
details of quality control methods). Reads were trimmed
using Trimmomatic, mapped to the human genome
(hg38, gencode v25) using STAR, counted using htseq,
and differential gene expression was analysed using
DESeq2.
Gene ontology and pathway analyses
The R package ‘GOseq’ was used to analyse significantly
differentially expressed (DE) genes and identify over or
under-represented gene ontology terms (see Additional
file 1 for details).
QIAGEN’s Ingenuity Pathway Analysis (IPA) (IPA®,
QIAGEN Redwood City, www.qiagen.com/ingenuity)
‘Canonical Pathways’ tool was used to identify pathways
with an enrichment of significantly DE genes and the
‘MicroRNA Target Filter’ tool was used to match signifi-
cantly DE miRNA (p < 0.01) to predicted or experimen-
tally observed mRNA targets with significant (FDR <
0.05) opposite expression changes in the mRNA RNA
sequencing data (see Additional file 1 for details).
RTqPCR
cDNA synthesis was performed using the high capacity
RNA-to-cDNA™ kit for mRNA and the TaqMan® Ad-
vanced miRNA cDNA Synthesis Kit for miRNA (Applied
Biosystems). RTqPCR was performed on the QuantStu-
dio™ 12 k Flex (Applied BioSystems) using TaqMan®
Gene Expression and Advanced miRNA Assays (full list
of assays in Additional Table 1). Relative expression was
calculated using the 2-ΔΔCt method compared to refer-
ence genes (PRDM4 and UBE2D2 for mRNA, miR-503-
5p and miR-425-5p for miRNA assays).
Transfection of human skeletal muscle cell line
An immortalised human skeletal muscle cell line, gener-
ated from primary human myoblasts, was cultured [11]
Table 1 Demographic and autoantibody status information for samples
PM (n = 7) DM (n = 7) IBM (n = 5) Control (n = 5)
% Female 57.1 57.1 40 20
Mean age 59.3 ± 7.2 50.6 ± 14.4 65.2 ± 4.6 44.6 ± 10.7





PM Polymyositis, DM Dermatomyositis, IBM Inclusion body myositis
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(refer to Additional file 1 for details). Cells were seeded
at 40,000 cells per well and incubated at 37 °C for 24 h
before transfection. Transfection was performed using
Lipofectamine RNAiMAX and mirVana™ miRNA mimic
for hsa-miR-96-5p (Assay ID MC10422) or negative con-
trol (Negative Control #1, Ambion). After transfection,
cells were incubated at 37 °C for 24 h. Total RNA was
isolated from cells using TRIzol® Reagent (Invitrogen)
and gene expression measured by RTqPCR as described
above.
Statistical analyses
RNAseq and pathway analyses false discovery rates were
calculated using the Benjamini-Hochberg method.
P-values for the RTqPCR analyses were calculated
using an independent T-test on delta Ct values from
each sample (Experimental Ct-Reference Ct) in the
subgroups.
Results
Differentially expressed genes and microRNAs in IIM
patients compared to controls
Overall, 129, 53 and 24 DE mRNAs were identified for
PM, DM and IBM compared to controls, respectively
(false discovery rate (FDR) < 0.05) (Fig. 1a, Add-
itional file 2). Analysis of the five anti-Jo-1 positive sam-
ples (4 PM and 1 DM) compared to controls identified
691 DE genes (Fig. 1a, Additional file 2). In analysis of
miRNAs, 4, 4, 7 and 3 miRNAs were DE for the PM,
DM, IBM and anti-Jo-1 positive subgroups compared to
controls, respectively (p < 0.01) (Fig. 1b, Additional file 3).
No DE miRNAs were identified at FDR < 0.05.
Innate immunity pathways are enriched for dysregulation
in PM and DM and the anti-Jo1 positive subset
GOseq analysis of genes differentially expressed in the
PM, DM and anti-Jo1 subgroups compared to controls
found that the categories with the most significant over-
representation of DE genes (Benjamini Hochberg
adjusted p-value< 0.05) were immune-related responses
including responses to type I interferon and viruses
(Additional file 4).
Similarly, when IPA was used to identify canonical
pathways with an over-representation of DE genes
‘Interferon signalling’ was the most significantly dysregu-
lated canonical pathway for the PM, DM and anti-Jo1
subgroups and predicted to be upregulated in all three
groups (−log p-value> 1.3 significant for pathway dysreg-
ulation and a z-score > 2 or < − 2 significant for predicted
activation or inhibition, respectively) (Fig. 2, Add-
itional file 5). The most significant pathways for PM
were interferon or interleukin (IL-6, IL-15 and IL-7) re-
lated and highlighted roles for JAK kinases in the signal-
ling of both of these groups of cytokines. The five most
significant pathways for DM were related to interferon
signalling and anti-viral innate immunity; particularly
the role of pattern recognition receptors, interferon
regulatory factors and STAT3 (Additional file 5). Group-
ing by anti-Jo1 positivity similarly identified pathways
related to interferon, interleukin, JAK kinases and anti-
viral innate immunity. Notably, the anti-Jo1 subgroup
had a higher ratio of dysregulated molecules to total
molecules in the ‘Interferon signalling’ pathway, a higher
proportion of molecules exclusive to type II interferon
signalling, including upregulation of Interferon gamma
receptor 1, and a higher activation score (z-score) com-
pared to the other clinical groups. Additionally, the anti-
Fig. 1 Significantly differentially expressed mRNA (a) and microRNA (b) in idiopathic inflammatory myopathy subgroups versus controls DM
Dermatomyositis, PM Polymyositis, IBM Inclusion Body Myositis Anti-Jo1 Anti-Jo1 autoantibody positive samples Generated from lists of
significantly differentially expressed mRNA (FDR < 0.05) and microRNA (p < 0.01) in RNA sequencing of whole blood from 7 PM, 7 DM, 5 IBM and
5 controls (4 PM and 1 DM were anti-Jo1 autoantibody positive) using Venny 2.1 [Oliveros, J.C. (2007–2015) Venny. An interactive tool for
comparing lists with Venn’s diagrams. http://bioinfogp.cnb.csic.es/tools/venny/index.html]
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Jo1 subgroup analysis highlighted T-helper cell-related
pathways which were not significantly dysregulated in
the other subgroups (Fig. 2, Additional file 5).
RTqPCR highlighted miR-96-5p and targets
The two most significantly DE miRNAs (p < 0.001),
miR-92a-1-5p and miR-96-5p, and two miRNAs DE in
our data (p < 0.01) which have previously been reported
to be DE in IIM, miR-10a-5p and miR-223-3p [12, 13],
were chosen for follow up by RTqPCR in a subset of
samples with sufficient remaining RNA (6 PM and 5 DM
(including 5 anti-Jo-1 positive), 4 IBM, and 4 controls).
MiR-96-5p had the highest degree of differential expres-
sion, upregulated for PM, DM and anti-Jo1, consistent
with the small RNA sequencing data, although the
RTqPCR data was only statistically significant for DM,
probably due to small sample size (Additional Table 2).
MiR-10a-5p was validated as significantly downregulated
in IBM. MiR-92a-1-5p and miR-223-3p were not signifi-
cantly DE in RTqPCR analysis of these samples.
Predicted targets of miR-96-5p which were downregu-
lated in the RNA sequencing data were identified using
the IPA microRNA target filter tool (Fig. 3). A subset of
the mRNAs identified with high confidence as predicted
targets (ADK and DAB1) or the most significant dysreg-
ulation in the RNA sequencing data (SLC4A10 and
CD28) (Fig. 3c) were measured by RTqPCR in samples
with remaining RNA (5 PM, 5 DM, (4 anti-Jo1 positive)
and 4 controls). ADK and CD28 were significantly
downregulated in anti-Jo1 samples, while SLC4A10 was
significantly downregulated across the PM, DM and
anti-Jo-1 subgroups (p < 0.05, Table 2). DAB1 was not
expressed at a detectable level.
Predicted targets of miR-96-5p which were downregu-
lated in our PM and anti-Jo1 subgroup RNA sequencing
data were identified using the IPA microRNA target fil-
ter tool and measured by RTqPCR in samples with fur-
ther remaining RNA (5 PM, 5 DM, (4 anti-Jo1 positive)
and 4 controls). Expression fold change was calculated
using the 2-ΔΔCt method and then converted to Log2
Fig. 2 Top ten canonical pathways enriched for dysregulation in anti-Jo1 positive samples compared to controls PM Polymyositis, DM
Dermatomyositis, IBM Inclusion Body Myositis, Anti-Jo1 Anti-Jo1 autoantibody positive subset of PM and DM, Th T-helper cell, IRF Interferon
regulatory factor, NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells, iNOS Inducible nitric oxide synthase. Data generated using
QIAGEN’s Ingenuity Pathway Analysis ‘Canonical Pathways’ tool on differential expression data from RNA sequencing of whole blood from 7 PM, 7
DM, 5 IBM and 5 non-myositis controls. The dashed line indicates the significance threshold of –log p-value > 1.3 (p-value < 0.05) for over-
representation of dysregulated genes in the pathway
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fold change values. P-values were calculated using an in-
dependent T-test on delta Ct values from each sample
(Experimental Ct-Reference Ct) in the subgroups.
Transfection of miR-96-5p mimic resulted in
downregulation of ADK
To investigate the impact of miR-96-5p on the expres-
sion of predicted mRNA targets downregulated in IIM
in a cell culture model relevant to IIM, human skeletal
muscle cells were transfected with miR-96-5p or nega-
tive control miRNA mimic. After 24 h, RNA was isolated
from cells and expression of miR-96-5p targets ADK,
CD28 and SLC4A10 was measured using RTqPCR.
Expression of ADK, but not CD28 or SLC4A10, was sig-
nificantly downregulated in cells transfected with miR-
96-5p (n = 5) compared to cells transfected with negative
control mimic (n = 3) suggesting that ADK is suppressed
by miR-96-5p in human skeletal muscle (Additional
Table 3).
Discussion
To our knowledge, this is the first study to simultan-
eously profile both miRNA and mRNA in IIM whole
blood using next generation RNA sequencing. Pathway
analyses highlighted enrichment of DE genes in innate
immune and anti-viral response pathways in PM and
Fig. 3 Networks of predicted targets of miR-96-5p downregulated in idiopathic inflammatory myopathy patients compared to controls QIAGEN’s
Ingenuity Pathway Analysis (IPA) ‘microRNA target filter’ predicted mRNA targets of miR-96-5p which are downregulated in RNA sequencing of
whole blood from (a) polymyositis (PM) (n = 7) and (b) anti-Jo1 positive PM and dermatomyositis (DM) samples (n = 5) compared to controls
(n = 5). No targets were identified in the DM subgroup. Red colouring indicates upregulation, green colouring indicates downregulation and
darker shades indicate greater fold change. (c) Summary of IPA microRNA target filter predicted targets. Confidence is ‘high’ if the TargetScan
database cumulative weighted context ++ score (CWCS) is − 0.4 or below, indicating a predicted repression of at least 25% and ‘moderate’ if the
CWCS is − 0.2 to − 0.4, indicating a predicted repression of 13–25%
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DM. Genes in the interferon signalling pathway were up-
regulated in PM and DM with an increased number of
upregulated genes and increased predicted pathway acti-
vation in the anti-Jo1 positive subset. This is consistent
with previous findings that an interferon score (based on
expression of 8 interferon response genes) was higher in
whole blood from IIM patients with autoantibodies
against RNA-binding proteins, including anti-Jo1, com-
pared to IIM patients with other or no autoantibodies
[14]. A larger proportion of the upregulated genes in the
anti-Jo1 group were from the type II interferon pathway
which is consistent with reports that anti-synthetase syn-
drome is associated with a prominent type II IFNγ sig-
nature in muscle biopsies [15, 16].
The overall number of significant DE genes was
much higher in the anti-Jo1 positive subset than in
the clinical groups compared to controls. Anti-Jo1
positivity in IIM is associated with a well-defined set
of symptoms, termed anti-synthetase syndrome.
Therefore, the higher number of DE genes in the
anti-Jo1 positive subset may be due in part to a more
homogenous sample allowing for more significant dif-
ferences to be identified when compared to controls.
We do not have data on features such as disease ac-
tivity, disease manifestations and treatments at time
of blood draw which may contribute to the striking
transcriptomic profile in this subset. T-helper (Th)
cell pathways were significantly enriched for dysregu-
lation in the anti-Jo1 subset but not for any of the
clinical groups. Since this analysis was performed on
whole blood, these findings may reflect greater differ-
ences in cell composition in samples from the anti-
Jo1 positive group compared to other IIM groups and
healthy controls. Analysis of differential gene
expression in T-cell subsets from different serological
groups within IIM may help to elucidate the role of
T-helper cells. RNA sequencing in CD4+ and CD8+
T-cells from PM and DM peripheral blood has shown
differential gene expression between PM and DM, es-
pecially for CD8+ cells, although the contribution of
autoantibody positivity to the differential expression
was not investigated [17].
In this study, whole blood was chosen as an abundant
source of RNA which may reflect systemic changes in
circulating immune cells in IIM. Further work is re-
quired to assess how these changes affect the main tar-
get tissue of IIM, skeletal muscle, and whether changes
in circulating microRNA in particular reflect changes in
expression in muscle tissue.
MicroRNA profiling identified 4, 4, 7 and 3 DE miR-
NAs for PM, DM, IBM and the anti-Jo1 positive subset,
respectively, with miR-96-5p significantly DE in PM,
DM and anti-Jo1 patients. To our knowledge this is the
first miRNA profile in IIM whole blood and therefore it
is not surprising that we found significantly differentially
expressed microRNA that had not been previously iden-
tified in IIM in other tissues. Studies have identified
serum miR-7 downregulation as a possible biomarker of
PM/DM which is further reduced in patients with ILD
[18, 19]. This miRNA may not have been identified in
our samples due to differential expression between cell
types within whole blood. For example, a study in Sjög-
ren’s syndrome found that miR-146a-5p was upregulated
in T-cells but downregulated in B-cells [20] and a study
in systemic sclerosis found that miR-618 was upregu-
lated in plasmacytoid dendritic cells but not significantly
DE in monocytes [21]. Therefore, to establish which cell
type within whole blood is driving these expression
changes and whether they reflect changes in expression
in skeletal muscle, expression of the identified DE
miRNA and mRNA should be measured in different
sample types such as plasma, serum and sorted periph-
eral blood mononuclear cells.
RTqPCR using samples with remaining RNA for four
miRNAs found differential expression consistent with
the RNA sequencing results for miR-96-5p and miR-
10a-5p, although upregulation of miR-96-5p only
reached statistical significance for DM, possibly due to
small sample sizes. Since miR-96-5p had the largest fold
changes in the RTqPCR analyses and has not been iden-
tified in IIM before, we investigated the predicted targets
of miR-96-5p which were downregulated in the RNA se-
quencing data. ADK, SLC4A10 and CD28 were validated
as downregulated in the anti-Jo1 subgroup by RTqPCR.
Transfection of human skeletal muscle cells with a miR-
96-5p mimic resulted in downregulation of ADK but not
SLC4A10 or CD28 expression, suggesting that miR-96-
5p binds and induces degradation of ADK in human
Table 2 RTqPCR of predicted miR-96-5p mRNA targets
identified in RNA sequencing in IIM patients versus controls
Subgroup RTqPCR RNAseq





ADK PM −0.64 0.87 0.0690 −0.75 0.3520
DM −0.49 0.78 0.0960 −0.56 0.8960
Anti-Jo1 −0.82 0.63 0.0290 −1.16 0.0337
CD28 PM −1.12 1.59 0.1240 −0.91 0.2780
DM −0.63 1.01 0.2840 −0.55 1.0000
Anti-Jo1 −1.50 1.21 0.0340 −1.34 0.0175
SLC4A10 PM −4.62 1.89 0.0010 −5.12 0.0002
DM −4.02 1.25 0.0010 −2.36 1.0000
Anti-Jo1 −5.28 0.96 2.40E-05 −8.86 8.36E-11
PM Polymyositis, DM Dermatomyositis, Anti-Jo1 Subset of PM and DM with
anti-Jo1 autoantibodies
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skeletal muscle. However, binding should be confirmed
experimentally and expression analysed in a larger num-
ber of whole blood samples and in other tissue types
including myositis muscle and sorted blood cells.
miR-96-5p has mainly been studied as an oncogenic
miRNA dysregulated in a variety of cancer types includ-
ing gastric, breast, ovarian and colorectal cancer [22–
25]. Adenosine Kinase (ADK) is an enzyme that converts
adenosine to adenosine monophosphate and adenosine
diphosphate. Both upregulation of miR-96-5p and defi-
ciency of ADK have previously been suggested to be as-
sociated with mitochondrial dysfunction [26, 27].
Modified reactive oxygen species production as a result
of mitochondrial dysfunction may be associated with
weakness in IIM [28]. Therefore, if miR-96-5p targeting
of ADK is confirmed, this may be an interesting avenue
for research in IIM.
The main limitation of this study was the limited sam-
ple size due to conservative use of samples from this rare
disease. Other limitations include the use of whole blood
with variable cellular composition, the higher proportion
of males in the control group and the use of samples
from patients who have varying degrees of disease sever-
ity and were on various treatments for IIM due to the
delay to IIM diagnosis, all of which may alter mRNA
and miRNA expression.
Conclusions
Overall, in this study pathway analyses have highlighted
enrichment of DE genes in innate immune and anti-viral
response pathways in PM and DM and replicated previ-
ous findings that interferon signalling is upregulated in
PM and DM and more highly upregulated and shifted
towards type II interferon signalling in the anti-Jo1 sub-
group [14, 15]. In addition, this study highlighted enrich-
ment of dysregulated genes in the T-helper cell
pathways in the anti-Jo1 positive subset and indicated a
possible role for miR-96-5p regulation of ADK in patho-
genesis of IIM.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s41927-020-00125-8.
Additional file 1. Supplementary Methods and Results
Additional file 2 Significant RNA sequencing differential expression in
polymyositis, dermatomyositis and inclusion body myositis patients
versus controls PM Polymyositis, DM Dermatomyositis, IBM Inclusion body
myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoantibodies
Data generated by DESeq2 analysis of RNA sequencing data from 7 PM, 7
DM, 5 IBM compared to 5 control whole blood samples. The table col-
umns are gene ids, log2 fold change, standard error for log2 fold change
(lfcSE), statistic value for the null hypothesis (stat), p-value, false discovery
rate (padj), and gene name.
Additional file 3 Significant microRNA sequencing differential
expression in polymyositis, dermatomyositis and inclusion body myositis
patients versus controls PM Polymyositis, DM Dermatomyositis, IBM
Inclusion body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1
autoantibodies Data generated by DESeq2 analysis of small RNA sequen-
cing data from 7 PM, 7 DM, 5 IBM compared to 5 control whole blood
samples. The table columns are mature microRNA ids, log2 fold change,
standard error for log2 fold change (lfcSE), statistic value for the null hy-
pothesis (stat), p-value, false discovery rate (padj), and mature microRNA
name.
Additional file 4 GOseq analysis of differentially expressed genes in
idiopathic inflammatory myopathy patients versus controls PM
Polymyositis, DM Dermatomyositis, IBM Inclusion body myositis, Anti-Jo1
Subset of PM and DM with anti-Jo1 autoantibodies GOseq analysis was
performed on significantly differentially expressed genes (FDR < 0.05)
from RNA sequencing of 7 PM, 7 DM, 5 IBM and 5 control whole blood
samples. The anti-Jo1 subgroup consists of 4 PM and 1 DM sample posi-
tive for anti-Jo1 autoantibodies. Columns are gene ontology category, p-
value for over-representation, Benjamini Hochberg adjusted p-value for
over-representation (FDR < 0.05 considered significant), p-value for under-
representation, number of differentially expressed genes in that category,
total number of genes in the gene ontology category, description of
gene ontology category (term) and type of ontology (BP biological
process, MF molecular function, CC cellular component).
Additional file 5 Canonical Pathways with an enrichment of
significantly differentially expressed genes in idiopathic inflammatory
myopathy patients PM Polymyositis, DM Dermatomyositis, IBM Inclusion
body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoanti-
bodies QIAGEN’s Ingenuity Pathway Analysis (IPA) ‘Canonical Pathways’
analysis was performed on differential expression results from RNA se-
quencing of 7 PM and 7 DM (5 anti-Jo1 autoantibody positive), 5 IBM and
5 control whole blood samples. Columns are IPA defined canonical path-
way, −log(p-value) for over-representation of dysregulated molecules in
the pathway (> 1.3 is considered significant), ratio of dysregulated mole-
cules to total molecules in pathway, activation score (z-score > 2 is signifi-
cant predicted activation, <− 2 is significant predicted inhibition, not
determined (ND) when IPA algorithm unable to generate a score) and a
list of dysregulated molecules in the pathway.
Additional file 6: Table S1. Assays used in RTqPCR experiments The
assay IDs for the TaqMan® Advanced miRNA assays and gene expression
assays used to assess reference genes (‘Reference selection’), for
validation of microRNA (‘miRNA validation’) and targets (‘mRNA
validation’) found to be dysregulated in RNA sequencing of whole blood
from idiopathic inflammatory myopathy patients compared to controls
and used to assess expression in human skeletal muscle cells transfected
with miRNA mimic compared to cells transfected with negative control
miRNA mimic (‘Transfection’). Table S2. RTqPCR to validate microRNA
identified in RNA sequencing in idiopathic inflammatory myopathy
patients versus controls PM Polymyositis, DM Dermatomyositis, IBM
Inclusion body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1
autoantibodies, IIM Idiopathic inflammatory myopathy, DE Differentially
expressed RTqPCR was performed on total RNA from 6 PM and 5 DM (in-
cluding 5 anti-Jo-1), 4 IBM, and 4 control whole blood samples. The
RTqPCR results are presented next to the RNA sequencing results for
these microRNA for comparison. Expression fold change was calculated
using the 2-ΔΔCt method and then converted to Log2 fold change values.
P-values were calculated using an independent T-test on delta Ct values
from each sample (Experimental Ct-Reference Ct) in the subgroups.
Table S3. RTqPCR results for skeletal muscle cells transfected with miR-
96-5p mimic compared to controls RTqPCR assays for the expression of
predicted miR-96-5p mRNA targets were performed on total RNA ex-
tracted from human skeletal muscle cells transfected with miR-96-5p
miRNA mimic (n = 5) and cells transfected with negative control miRNA
mimic (n = 3). Expression fold change was calculated using the 2-ΔΔCt
method and then converted to Log2 fold change values. P-values were
calculated using an independent T-test on delta Ct values from each
sample (Experimental Ct-Reference Ct).
Abbreviations
IIM: Idiopathic inflammatory myopathy; ADK: Adenosine kinase;
cDNA: Complementary DNA; DAB1: DAB adaptor protein 1; DE: Differentially
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expressed; DM: Dermatomyositis; FDR: False discovery rate; IBM: Inclusion
body myositis; IPA: Ingenuity pathway analysis; miRNA: MicroRNA;
MRTB: Myositis research tissue bank; PM: Polymyositis; PRDM4: PR Domain
Zinc Finger Protein 4; RTqPCR: Reverse transcription quantitative polymerase
chain reaction; SLC4A10: Solute carrier family 4 member 10;
UBE2D2: Ubiquitin conjugating enzyme E2 D2
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